Core Viewpoint - Corning Jereh Pharmaceutical-B (09966) announced a share buyback program, indicating that the current market price does not reflect the company's intrinsic value and expressing confidence in its business outlook and future prospects [1] Summary by Relevant Sections - Share Buyback Authorization - The board of directors resolved to repurchase ordinary shares from the open market, with a maximum amount of HKD 20 million [1] - This buyback is subject to approval at the shareholders' annual general meeting scheduled for June 12, 2025 [1] - Rationale for Buyback - The board believes that the current trading price of the shares does not accurately reflect the company's intrinsic value [1] - The buyback is seen as a demonstration of the company's confidence in its business outlook and future prospects [1] - The company aims to benefit from this buyback and create value for its shareholders [1] - Financial Position - The board is confident that the company's current financial resources are sufficient to support the proposed share buyback while maintaining a robust financial position [1]
康宁杰瑞制药-B拟进行场内股份购回